spacer
home > pmps > spring 2018 > time is short
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Time Is Short

Serialisation of prescription medicines will become mandatory in the EU on 9 February 2019, resulting in new labelling requirements as a prerequisite for market access. Other countries and regions are already further ahead. Therefore, pharmaceutical manufacturers must promptly invest in suitable solutions. Simultaneously, late-stage customisation is becoming increasingly important due to continuously decreasing batch sizes. If both digital printing processes can be combined in one step, the opportunity to implement compliant and costoptimised production will arise.

The first logical step is considering where serialisation can most sensibly be performed in the production process. Is it:

  • During the offset printing of sheets for the later folding cartons?
  • In a contract packaging facility?
  • In special logistics centres?
  • In the packaging lines of pharma manufacturers?

The solution chosen by the company will depend on the existing infrastructure as well as several other factors.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stefan Rowinski, Product Manager at Atlantic Zeiser’s pharma and packaging solutions division, specialises in the development and marketing of system solutions for serialisation, late-stage customisation, and track-and-trace applications. Additionally, his expertise includes a deep knowledge of processes and workflow in sensitive environments and data management solutions. Prior to his position as a product manager, Stefan spent years designing, implementing and planning one-stop solutions for product individualisation and headed the projects to implement these solutions. 
spacer
Stefan Rowinski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

c-LEcta signs Europe sales and distribution agreement with VWR for c-LEcta’s DENARASE®

• DENARASE® is now available through VWR’s sales channels in Europe • VWR, part of Avantor, is a leading global provider of product and service solutions to laboratory and production customers • Cooperation harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement